Neurosense Therapeutics is trading 7.63% up at $0.45, apparently amid continued volatility following the September 4 gain, with no clear company-specific announcement identified for September 8, 2026.
- Recent coverage identifies a September 3 analyst initiation as the latest notable company item.
- Official announcement listings do not indicate a fresh catalyst.
- Major U.S. indices declined on September 8, so the global market backdrop does not clearly explain the after-hours rise.